



MODULE 1 REGIONAL ADMINISTRATIVE INFORMATION

**SECTION** 1.3 – PRODUCT INFORMATION

**SUB SECTION** 1.3.1 SUMMARY OF PRODUCT CHARACTERISTICS

# 1. Name of the medicinal product

Omol tablets

### 2. Qualitative and quantitative composition

Omol tablets: Each uncoated tablet contains Paracetamol 500 mg.

#### 3. Pharmaceutical form

White to off-white, flat beveled edge, circular, uncoated tablet having embossing "101" on one side and break-line on other side of the tablet.

#### 4. Clinical particulars

# 4.1 Therapeutic Indication

Omol Tablets is a mild analgesic and antipyretic, and is recommended for the treatment of most painful and febrile conditions, for example, headache including migraine and tension headaches, toothache, backache, rheumatic and muscle pains, dysmenorrhoea, sore throat, and for relieving the fever, aches and pains of colds and flu. Also recommended for the symptomatic relief of pain due to non-serious arthritis.

#### 4.2 Posology and method of administration

Posology:

Adults:

Two tablets up to four times daily as required.

Children:

6 - 12 years: Half to one tablet three or four times daily as required. Not suitable for children under six years of age. Children should not be given Omol Tablets for more than 3 days without consulting a doctor.

These doses should not be repeated more frequently than every four hours nor should more than four doses be given in any 24 hour period.

Route of Administration: Oral

(Paracetamol tablets 500 mg)



MODULE 1 REGIONAL ADMINISTRATIVE INFORMATION

**SECTION** 1.3 – PRODUCT INFORMATION

**SUB SECTION** 1.3.1 SUMMARY OF PRODUCT CHARACTERISTICS

#### 4.3 Contraindications

Hypersensitivity to Paracetamol or any of the other constituents.

### 4.4 Special warnings and precautions for use

Care is advised in the administration of Paracetamol to patients with renal or hepatic impairment.

The hazard of overdose is greater in those with non-cirrhotic alcoholic liver disease.

Do not exceed the stated dose.

Patients should be advised to consult their doctor if their headaches become persistent.

Patients should be advised not to take other Paracetamol-containing products concurrently.

Patients should be advised to consult a doctor if they suffer from non-serious arthritis and need to take painkillers every day.

If symptoms persist consult your doctor.

Keep out of the reach and sight of children.

#### 4.5 Interaction with other medicinal products and other forms of interaction

The speed of absorption of Paracetamol may be increased by metoclopramide or Domperidone and absorption reduced by colestyramine. The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular daily use of Paracetamol with increased risk of bleeding; occasional doses have no significant effect.

# 4.6 Pregnancy and lactation

Epidemiological studies in human pregnancy have shown no ill effects due to Paracetamol used in the recommended dosage, but patients should follow the advice of their doctor regarding its use. Paracetamol is excreted in breast milk but not in a clinically significant amount. Available published data do not contraindicate breast feeding.



(Paracetamol tablets 500 mg)

MODULE 1 REGIONAL ADMINISTRATIVE INFORMATION

**SECTION** 1.3 – PRODUCT INFORMATION

**SUB SECTION** 1.3.1 SUMMARY OF PRODUCT CHARACTERISTICS

### 4.7 Effects on ability to drive and use machines

None

#### 4.8 Undesirable effects

Adverse events of Paracetamol from historical clinical trial data are both infrequent and from small patient exposure. Accordingly, events reported from extensive post-marketing experience at therapeutic/labelled dose and considered attributable are tabulated below by system class. Due to limited clinical trial data, the frequency of these adverse events is not known (cannot be estimated from available data), but post-marketing experience indicates that adverse reactions to Paracetamol are rare and serious reactions are very rare.

### Post marketing data

<b>Body System</b>	Undesirable effect
Blood and lymphatic system disorders	Thrombocytopenia Agranulocytosis
Immune system disorders	Anaphylaxis Cutaneous hypersensitivity reactions including skin rashes, angiodema and Stevens Johnson syndrome/toxic epidermal necrolysis
Respiratory, thoracic and mediastinal disorders	Bronchospasm*
Hepatobiliary disorders	Hepatic dysfunction

#### 4.9 Overdose

Liver damage is possible in adults who have taken 10g or more of paracetamol. Ingestion of 5g or more of paracetamol may lead to liver damage if the patient has risk factors (see below).

(Paracetamol tablets 500 mg)



MODULE 1 REGIONAL ADMINISTRATIVE INFORMATION

**SECTION** 1.3 – PRODUCT INFORMATION

**SUB SECTION** 1.3.1 SUMMARY OF PRODUCT CHARACTERISTICS

#### Risk factors

If the patient:

**a,** Is on long term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St John's Wort or other drugs that induce liver enzymes.

Or

**b,** Regularly consumes ethanol in excess of recommended amounts.

Or

c, Is likely to be glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.


#### **Symptoms**

Symptoms of paracetamol overdosage in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema, and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported.

### Management

Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of overdose or the risk of organ damage. Management should be in accordance with established treatment guidelines, see BNF overdose section.

Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma paracetamol concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is obtained up to 8





MODULE 1 REGIONAL ADMINISTRATIVE INFORMATION

**SECTION** 1.3 – PRODUCT INFORMATION

**SUB SECTION** 1.3.1 SUMMARY OF PRODUCT CHARACTERISTICS

hours post-ingestion. The effectiveness of the antidote declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral methionine may be a suitable alternative for remote areas, outside hospital. Management of patients who present with serious hepatic dysfunction beyond 24h from ingestion should be discussed with the NPIS or a liver unit.

## 5. Pharmacological properties

## 5.1 Pharmacodynamic properties

Paracetamol is an antipyretic analgesic. The mechanism of action is probably similar to that of aspirin and dependant on the inhibition of prostaglandin synthesis. This inhibition appears, however to be on a selective basis.

# 5.2 Pharmacokinetic properties

Paracetamol is rapidly and almost completely absorbed from the gastrointestinal tract. The concentration in plasma reaches a peak in 30 to 60 minutes and the plasma half-life is 1 - 4 hours after therapeutic doses. Paracetamol is relatively uniformly distributed throughout most body fluids. Binding of the drug to plasma proteins is variable; 20 to 30% may be bound at the concentrations encountered during acute intoxication. Following therapeutic doses 90 - 100% of the drug may be recovered in the urine within the first day. However, practically no paracetamol is excreted unchanged and the bulk is excreted after hepatic conjugation.

#### 5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

#### 6. Pharmaceutical particulars


## 6.1 List of excipients

Polyvinyl Pyrrolidone

Starch

Stearic acid

Sodium starch glycolate





MODULE 1 REGIONAL ADMINISTRATIVE INFORMATION

**SECTION** 1.3 – PRODUCT INFORMATION

**SUB SECTION** 1.3.1 SUMMARY OF PRODUCT CHARACTERISTICS

# **6.2** Incompatibilities

Not applicable

#### 6.3 Shelf life

3 years

# 6.4 Special precautions for storage

Keep this out of reach of children. Store below 30°C. Protect from light and moisture.

### 6.5 Nature and contents of container

PVDC / PE coated PVC blisters, backed up with aluminium foil.

# 6.6 Special precautions for disposal and other handling

No special requirements for storage.

# 7. Marketing authorization holder

National Pharmaceutical Industries Co. (SAOG)

P.O Box 120, Road No.15

Postal Code 124

Rusayl, Sultanate of Oman

### 8. Date of revision of text

Rev No: 00, Rev.Date: 11/16